Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study.

Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, Aaby P, Laursen AL, Wejse C, Eugen-Olsen J; Bissau HIV cohort study group.

BMJ Open. 2012 Nov 14;2(6). pii: e001587. doi: 10.1136/bmjopen-2012-001587. Print 2012.

3.

Clinical predictors cannot replace biological predictors in HIV-2 infection in a community setting in West Africa.

Gourlay AJ, van Tienen C, Dave SS, Vincent T, Rowland-Jones SL, Glynn JR, Whittle HC, van der Loeff MF.

Int J Infect Dis. 2012 May;16(5):e337-43. doi: 10.1016/j.ijid.2012.01.001. Epub 2012 Mar 2.

4.

Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study.

Langkilde A, Petersen J, Klausen HH, Henriksen JH, Eugen-Olsen J, Andersen O.

PLoS One. 2012;7(12):e51698. doi: 10.1371/journal.pone.0051698. Epub 2012 Dec 10. Erratum in: PLoS One. 2014;9(4):e94152.

5.

High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.

Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):23-31.

PMID:
15851910
6.

The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.

Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I.

Int J Tuberc Lung Dis. 2002 Aug;6(8):686-92.

PMID:
12150480
7.

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Review.

PMID:
20238364
8.

An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.

Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR.

Clin Infect Dis. 2011 Nov;53(9):952-60. doi: 10.1093/cid/cir606. Epub 2011 Sep 26.

9.

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.

Clin Infect Dis. 2008 Mar 15;46(6):933-40. doi: 10.1086/528861.

PMID:
18271750
10.

Very early anthropometric changes after antiretroviral therapy predict subsequent survival, in karonga, Malawi.

Maman D, Glynn JR, Crampin AC, Kranzer K, Saul J, Jahn A, Mwinuka V, Ngwira MH, Mvula H, Munthali F, McGrath N.

Open AIDS J. 2012;6:36-44. doi: 10.2174/1874613601206010036. Epub 2012 Apr 27.

11.

Total lymphocyte count is a good marker for HIV-related mortality and can be used as a tool for starting HIV treatment in a resource-limited setting.

Oudenhoven HP, Meijerink H, Wisaksana R, Oetojo S, Indrati A, van der Ven AJ, van Asten HA, Alisjahbana B, van Crevel R.

Trop Med Int Health. 2011 Nov;16(11):1372-9. doi: 10.1111/j.1365-3156.2011.02870.x. Epub 2011 Sep 1.

12.

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B; Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group.

JAMA. 2001 Nov 28;286(20):2560-7.

PMID:
11722270
13.
14.
15.

Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia.

van Griensven J, Thai S.

Trans R Soc Trop Med Hyg. 2011 Dec;105(12):694-703. doi: 10.1016/j.trstmh.2011.08.007. Epub 2011 Oct 2.

PMID:
21962614
16.

Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.

Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, Downing R, Coutinho A, Solberg P, Alexander LN, Tappero J, Campbell J, Moore DM.

BMJ. 2011 Nov 9;343:d6792. doi: 10.1136/bmj.d6792.

17.

Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.

Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, Martin JN.

AIDS. 2011 Nov 13;25(17):2123-31. doi: 10.1097/QAD.0b013e32834c4ac1.

18.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
19.

Weight change at 1 mo of antiretroviral therapy and its association with subsequent mortality, morbidity, and CD4 T cell reconstitution in a Tanzanian HIV-infected adult cohort.

Sudfeld CR, Isanaka S, Mugusi FM, Aboud S, Wang M, Chalamilla GE, Giovannucci EL, Fawzi WW.

Am J Clin Nutr. 2013 Jun;97(6):1278-87. doi: 10.3945/ajcn.112.053728. Epub 2013 May 1.

20.

Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand.

Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group.

PLoS One. 2012;7(8):e43375. Epub 2012 Aug 15.

Supplemental Content

Support Center